DxRuptive, Inc. retweetledi

A fascinating empirical study of § 101 rejections for *non*-DNA #patents after #Myriad in @NatureBiotech from the @Cambridge_Uni Law, Medicine & Life Sciences group. tl;dr: Myriad is used to invalidate a lot more than gDNA clams. nature.com/articles/nbt.4…
English


























